1. Home
  2. BVS vs TBPH Comparison

BVS vs TBPH Comparison

Compare BVS & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bioventus Inc.

BVS

Bioventus Inc.

HOLD

Current Price

$11.85

Market Cap

783.2M

Sector

Health Care

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$16.86

Market Cap

908.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BVS
TBPH
Founded
2011
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
783.2M
908.9M
IPO Year
2016
2013

Fundamental Metrics

Financial Performance
Metric
BVS
TBPH
Price
$11.85
$16.86
Analyst Decision
Strong Buy
Buy
Analyst Count
3
6
Target Price
$14.00
$18.40
AVG Volume (30 Days)
706.8K
906.3K
Earning Date
05-06-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
163.46
279.13
EPS
0.04
N/A
Revenue
$568,087,000.00
$15,386,000.00
Revenue This Year
$7.52
$8.46
Revenue Next Year
$7.06
N/A
P/E Ratio
$287.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.81
$10.82
52 Week High
$12.53
$21.03

Technical Indicators

Market Signals
Indicator
BVS
TBPH
Relative Strength Index (RSI) 58.18 50.57
Support Level $8.04 $16.17
Resistance Level $12.53 $17.21
Average True Range (ATR) 0.54 0.11
MACD -0.07 -0.04
Stochastic Oscillator 41.30 12.50

Price Performance

Historical Comparison
BVS
TBPH

About BVS Bioventus Inc.

Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.

Share on Social Networks: